Video

Dr. Covey on Recent and Future Changes to the NCCN Guidelines for HCC

Author(s):

Anne Covey, MD, interventional radiologist, Memorial Sloan Kettering Cancer Center, discusses recent and future changes to locoregional treatment approaches for hepatocellular carcinoma (HCC).

Anne Covey, MD, interventional radiologist, Memorial Sloan Kettering Cancer Center, discusses recent and future changes to locoregional treatment approaches for hepatocellular carcinoma (HCC).

For patients with limited disease (small HCC), the guidelines now include ablation as a potentially curative option. Prior to this change, surgery and transplant were the only curative therapies, Covey says.

The locoregional therapy panel has also expanded to include patients with minimal extrahepatic disease who are candidates for arterially directed therapies. Finally, Covey says, select patients who have tumor in the portal vein—this used to be considered a contraindication—can now receive locoregional therapy.

Covey says there needs to be work done to include imaging follow-up for locoregional therapy in NCCN guidelines. There are several techniques to evaluate response, she says, but the information should be included in guidelines.

<<<

View more from the 2016 NCCN Annual Conference

Related Videos
Leah Backhus, MD, MPH, FACS, professor, University Medical Line, Cardiothoracic Surgery, co-director, Thoracic Surgery Clinical Research Program, associate program director, Thoracic Track, CT Surgery Residency Training Program, Thelma and Henry Doelger Professor of Cardiovascular Surgery, Stanford Medicine; chief, Thoracic Surgery, VA Palo Alto
Roy S. Herbst, MD, PhD, Ensign Professor of Medicine (Medical Oncology), professor, pharmacology, deputy director, Yale Cancer Center; chief, Medical Oncology, director, Center for Thoracic Cancers, Yale Cancer Center and Smilow Cancer Hospital; assistant dean, Translational Research, Yale School of Medicine
Sheldon M. Feldman, MD
Rita Mukhtar, MD
Lajos Pusztai, MD, DPhil
Hope S. Rugo, MD
5 KOLs are featured in this panel.
5 KOLs are featured in this panel.
Ciara Kelly, MBBCh, BAO
Mark Agulnik, MD